EFPIA's EBE Names New Executive Director

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 04-11-2015 15:51


The board of the European Biopharmaceutical Enterprises, a specialized group with the European Federation of Pharmaceutical Industries and Associations (EFPIA), has appointed Barbara Freischem as the new executive director of the EBE. She will take up her post on June 29, 2015.

In this role, she will be responsible for implementing the EBE outreach and advocacy plans in 2015. She will also work on promoting EBE’s overall priorities for supporting its recently updated vision of being the reference industry organization for biotech and advanced therapies and for interacting with key company, public, and private stakeholders.

Currently, Ms. Freischem works in the Scientific and Technical Department of the World Organization for Animal Health, Paris, France, with responsibilities for veterinary products, including antimicrobials and antimicrobial resistance, and animal health research coordination. Her experience further included: working for the German national registration authority for veterinary medicines and the European Medicines Agency, where her duties included oversight for pharmacovigilance for veterinary medicines; global head, pharmacovigilance for Novartis Animal Health; and the executive director of the International Federation for Animal Health, the global representative body of the animal health industry.

Source: EFPIA


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription